Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carotid Atherosclerosis
Conditions
Carotid Atherosclerosis
Trial Timeline
Apr 1, 2009 → Oct 1, 2010
NCT ID
NCT00804843About Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin
Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin is a phase 2 stage product being developed by Merck for Carotid Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00804843. Target conditions include Carotid Atherosclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00804843 | Phase 2 | Completed |
Competing Products
9 competing products in Carotid Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abciximab | Eli Lilly | Phase 1/2 | 41 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| simvastatin + placebo | Merck | Pre-clinical | 23 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Rimonabant + Placebo (for Rimonabant) | Sanofi | Phase 3 | 76 |
| Gadobutrol (Gadovist, BAY86-4875) | Bayer | Phase 3 | 74 |